Should Routine Screening for Prostate-Specific Antigen Be Recommended?

Abstract

To estimate the prevalence and predictors of Prostate-Specific Antigen (PSA) screening among Medicare beneficiary men using machine learning algorithms.

The rising prevalence of androgen deprivation among older American men since the advent of prostate‐specific antigen testing: a population‐based cohort study

“…The relatively high prevalence of ADT among men in the USA Medicare population, at ≈3%, might be related to time trends in prostate cancer mortality observed in the USA. Some have opined that the trend toward lower prostate cancer mortality might be related to more intensive screening and aggressive treatment for early‐stage disease [28]. However, similar trends are apparent in the UK in the absence of much screening [29].…”

The rationale for the ERSPC trial: will it improve the knowledge base on prostate cancer screening?

“…In summary, no consensus has emerged in the past 10 years within the scientific community about interpreting the results available to date, or between different international organizations and national societies issuing recommendations about prostate cancer. Prostate cancer screening remains a controversial issue [29,30]. No conclusive evidence showing either a sufficient reduction in mortality, or lack of such effect, has emerged since the start of ERSPC trial a decade ago [31].…”

Preventive Health Issues for Individuals in Jails and Prisons

“…Complications from some treatments, however, may last a lifetime, including urinary incontinence and impotence following radical prostatectomy and sexual and bowel dysfunction following radiation therapy; although, other treatments or adjunctive therapies, such as hormonal intervention, have shown promise of survival advantage with early treatment. 95 The general recommendation is for the clinician to educate patients about the disease, including their personal risks, the availability and limitations of screening tests, and the potential risks and benefits of diagnostic tests and treatments. The patient should be part of the decision to screen.…”